RenovoRx, Inc. (RNXT)
1.16
+0.02
(+1.75%)
USD |
NASDAQ |
Oct 19, 12:50
RenovoRx Cash from Operations (Annual) : -10.97M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -10.97M |
| December 31, 2024 | -9.125M |
| December 31, 2023 | -10.26M |
| December 31, 2022 | -8.811M |
| Date | Value |
|---|---|
| December 31, 2021 | -5.916M |
| December 31, 2020 | -3.528M |
| December 31, 2019 | -3.35M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Enanta Pharmaceuticals, Inc. | -19.27M |
| Travere Therapeutics, Inc. | 37.78M |
| REGENXBIO, Inc. | -123.96M |
| Krystal Biotech, Inc. | 200.86M |
| ACADIA Pharmaceuticals, Inc. | 109.84M |